<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665700</url>
  </required_header>
  <id_info>
    <org_study_id>1434-0003</org_study_id>
    <nct_id>NCT04665700</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are Tolerated</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single and Multiple Rising Doses of BI 764198 in Japanese Healthy Male Subjects (Double-blind, Randomised, Placebo-controlled Within Dose Groups, Parallel Group Design)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of this trial are to investigate safety and tolerability of BI 764198 in&#xD;
      healthy male subjects following oral administration of single dose and multiple rising doses&#xD;
      per day over 14 days.&#xD;
&#xD;
      Secondary objectives are the exploration of pharmacokinetics (PK) of BI 764198 after single&#xD;
      and multiple oral dosing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2021</start_date>
  <completion_date type="Actual">October 16, 2021</completion_date>
  <primary_completion_date type="Actual">October 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This trial consists of a single dose part and a multiple rising dose (MRD) part. The first dose group is conducted in the single dose part and the second dose group onwards are conducted in the MRD part.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage [%] of subjects with drug-related adverse events</measure>
    <time_frame>Up to 34 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>After single dose: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>Up to 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>After single dose: Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>Up to 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>After the last dose of multiple dose segment: AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>Up to 22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>After the last dose of multiple dose segment: Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>Up to 22 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 764198 Single dose part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 764198 Multiple dose low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 764198 Multiple dose medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 764198 Multiple dose high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 764198</intervention_name>
    <description>BI 764198</description>
    <arm_group_label>BI 764198 Multiple dose high</arm_group_label>
    <arm_group_label>BI 764198 Multiple dose low</arm_group_label>
    <arm_group_label>BI 764198 Multiple dose medium</arm_group_label>
    <arm_group_label>BI 764198 Single dose part</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects according to the assessment of the investigator, as based on a&#xD;
             complete medical history, including a physical examination, vital signs (BP, PR),&#xD;
             12-lead ECG, and clinical laboratory tests&#xD;
&#xD;
          -  Japanese ethnicity, according to the following criteria: born in Japan, have lived&#xD;
             outside of Japan &lt;10 years, and have parents and grandparents who are Japanese&#xD;
&#xD;
          -  Age of 20 to 45 years at screening (inclusive)&#xD;
&#xD;
          -  BMI of 18.5 to 25.0 kg/m2 (inclusive)&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the trial, in&#xD;
             accordance with GCP and local legislation&#xD;
&#xD;
          -  Willingness to comply with contraception requirements. Subjects who are sexually&#xD;
             active must use adequate contraception methods throughout the trial and until three&#xD;
             months after the last administration of trial medication. Adequate methods are:&#xD;
&#xD;
               -  A vasectomy performed at least 1 year prior to screening and with medical&#xD;
                  assessment of the surgical success or&#xD;
&#xD;
               -  Surgical sterilisation, including bilateral tubal occlusion, hysterectomy or&#xD;
                  bilateral oophorectomy, of the subject's female partner or&#xD;
&#xD;
               -  The use of condoms, if the female partner uses an adequate contraception method&#xD;
                  in addition, e.g., intrauterine device (IUD), or hormonal contraception, such as&#xD;
                  implants and injectables*, combined with oral or vaginal contraceptives, that&#xD;
                  started at least 2 months prior to first drug administration, or barrier method,&#xD;
                  e.g., diaphragm with spermicide* * hormonal contraception via implants and&#xD;
                  injectables, and diaphragm with spermicide are not approved in Japan Unprotected&#xD;
                  sexual intercourse with a pregnant partner is not allowed throughout the trial&#xD;
                  and until three months after the last administration of trial medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding in the medical examination (including BP, PR or ECG) deviating from normal&#xD;
             and assessed as clinically relevant by the investigator&#xD;
&#xD;
          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,&#xD;
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the&#xD;
             range of 50 to 90 bpm&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance&#xD;
&#xD;
          -  Any evidence of a concomitant disease assessed as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Cholecystectomy or other surgery of the gastrointestinal tract that could interfere&#xD;
             with the pharmacokinetics of the trial medication (except appendectomy or simple&#xD;
             hernia repair)- Diseases of the central nervous system (including but not limited to&#xD;
             any kind of seizures or stroke), and other relevant neurological or psychiatric&#xD;
             disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or blackouts Further&#xD;
             exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SOUSEIKAI Sumida Hospital</name>
      <address>
        <city>Tokyo, Sumida-ku</city>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

